# FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy

> **NCT04491084** · PHASE1,PHASE2 · TERMINATED · sponsor: **Albert Einstein College of Medicine** · enrollment: 5 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Lung Cancer

## Interventions

- **DRUG:** FLT3 Ligand (CDX-301)
- **BIOLOGICAL:** anti-CD40 antibody (CDX-1140)
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT04491084
- **Lead sponsor:** Albert Einstein College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-01
- **Primary completion:** 2022-08-18
- **Final completion:** 2022-08-18
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2024-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04491084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04491084, "FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04491084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*